Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential against gemcitabine-resistant PDAC

While poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) have achieved specific clinical benefits in a subset of pancreatic ductal adenocarcinoma (PDAC) patients, the potential role of the PARPi niraparib in PDAC necessitates further exploration. In this study, we demonstrated that Ni...

Full description

Bibliographic Details
Published in:	Translational Oncology
Main Authors:	Zehui Yao, Huihui Zhang, Kewei Huang, Guizhong Huang, Pu Xi, Lingmin Jiang, Dailei Qin, Fan Chen, Shengping Li, Ran Wei
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Subjects:	Pancreatic ductal adenocarcinoma Niraparib Autophagy Gemcitabine-resistance
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523324003334

Similar Items

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
by: Feng Shao, et al.
Published: (2018-06-01)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
by: Jane E. Rogers, et al.
Published: (2020-08-01)

Epithelial–Mesenchymal Transition Suppression by ML210 Enhances Gemcitabine Anti-Tumor Effects on PDAC Cells
by: Keisuke Takemura, et al.
Published: (2025-01-01)

The synergism of Clinacanthus nutans Lindau extracts with gemcitabine: downregulation of anti-apoptotic markers in squamous pancreatic ductal adenocarcinoma
by: Ling-Wei Hii, et al.
Published: (2019-09-01)

Efficacy and safety of the S-1, nab-paclitaxel, and gemcitabine triplet regimen in patients with resected pancreatic ductal adenocarcinoma
by: Donghui Ran, et al.
Published: (2025-09-01)

Patient Selection for the Use of Niraparib in Advanced Ovarian Cancer: A Review
by: Gonzalez A, et al.
Published: (2024-12-01)

Real-World Safety of Niraparib for Maintenance Treatment of Ovarian Cancer in Canada
by: Qi Guan, et al.
Published: (2024-06-01)

Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma
by: Wenjie Liu, et al.
Published: (2025-04-01)

TSPAN15 sustains ITGB1 stability to block gemcitabine-induced ferroptosis in pancreatic ductal adenocarcinoma through the FAK/AKT/Mtor-gpx4 cascade
by: Peng Nan, et al.
Published: (2025-09-01)

A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers
by: David Starks, et al.
Published: (2023-09-01)

The Development and Testing of a Patient Decision Aid for Individuals with Homologous Recombinant Proficient Ovarian Cancer Who Are Considering Niraparib Maintenance Therapy
by: Laura Hopkins, et al.
Published: (2024-03-01)

Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma
by: Keisuke Okuno, et al.
Published: (2023-01-01)

Combined use of niraparib enhanced the inhibitory effect of Anti-GD2 antibody on osteosarcoma cells
by: Chen Wenyao, et al.
Published: (2024-07-01)

Efficacy of oral ferric citrate hydrate treatment for anemia caused by niraparib: a case report
by: Hiroshi Kobayashi, et al.
Published: (2022-11-01)

A case of niraparib PARP-Inhibitor induced Sweet Syndrome in gynecologic cancer
by: Nora Badiner, et al.
Published: (2023-04-01)

PAK4 inhibition significantly potentiates Gemcitabine activity in PDAC cells via inhibition of Wnt/β-catenin, p-ERK/MAPK and p-AKT/PI3K pathways
by: Charudatt Samant, et al.
Published: (2023-09-01)

Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective
by: Hanqiao Shao, et al.
Published: (2024-09-01)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
by: Zong Y, et al.
Published: (2020-12-01)

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) caused by niraparib: a novel antineoplastic agent
by: Irene Vázquez-Barrera, et al.
Published: (2025-10-01)

The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China
by: Jing Ni, et al.
Published: (2021-05-01)

Interstitial Lung Disease Associated with Agaricus blazei Murill in a Patient with Pancreatic Ductal Adenocarcinoma Receiving Gemcitabine-Based Therapy
by: Naoto Iwai, et al.
Published: (2022-03-01)

An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma
by: Zhijun Xiao, et al.
Published: (2021-12-01)

Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer
by: Jinyu Meng, et al.
Published: (2021-10-01)

Real-world TRAE association between niraparib and platinum-based chemotherapy
by: Linli Wang, et al.
Published: (2024-06-01)

Niraparib restricts intraperitoneal metastases of ovarian cancer by eliciting CD36-dependent ferroptosis
by: Ning Jin, et al.
Published: (2025-03-01)

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting
by: Mauro Francesco Pio Maiorano, et al.
Published: (2023-09-01)

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer
by: Whitney S Graybill, et al.
Published: (2024-12-01)

Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma
by: Kaidong Liu, et al.
Published: (2022-08-01)

Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
by: Yin Shi, et al.
Published: (2023-07-01)

Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study
by: Chen Chang, et al.
Published: (2021-05-01)

Adverse Event Management in Patients with Platinum-Resistant Ovarian Cancer Treated with Niraparib and Anlotinib: Updates from the Phase II, Multi-Center ANNIE Study
by: Deng T, et al.
Published: (2025-07-01)

Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma
by: Keisuke Okuno, et al.
Published: (2022-09-01)

Niraparib for the treatment of metastatic ccRCC in a patient with CDK12 and RAD51C mutations: a case report
by: Xiaolong Yue, et al.
Published: (2024-06-01)

Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance
by: Desirèe Speranza, et al.
Published: (2025-04-01)

Adjuvant 5‐fluorouracil and portal vein infusion chemotherapy followed by gemcitabine for pancreatic cancer
by: Minoru Kitago, et al.
Published: (2024-07-01)

Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review
by: Jiajun Li, et al.
Published: (2025-07-01)

Correction: Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review
by: Jiajun Li, et al.
Published: (2025-07-01)

ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis
by: Xiaohong Liu, et al.
Published: (2025-08-01)

A novel RP-HPLC stability-indicating method for simultaneous estimation of Niraparib and Abiraterone in synthetic mixtures and combined tablet formulations
by: Krishnaphanisri Ponnekanti, et al.
Published: (2025-05-01)

Short-term starvation synergistically enhances cytotoxicity of Niraparib via Akt/mTOR signaling pathway in ovarian cancer therapy
by: Wang Zhi, et al.
Published: (2022-01-01)